Instituto de Investigación Biomédica de Salamanca (IBSAL)
Research facility
Location:
Salamanca,
Spain (ES)
ROR: https://ror.org/03em6xj44
Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment (2022)
Reinoso-Segura M, Caballero-Velazquez T, Herrera P, Patriarca F, Fanin R, Bruno B, Einsele H, et al.
Journal article
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma (2022)
Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, et al.
Journal article
Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network (2018)
Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, et al.
Journal article, Review article